Overview

Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

Status:
Withdrawn
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, docetaxel, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with docetaxel and capecitabine works in treating patients with cancer of unknown primary origin.
Phase:
Phase 2
Details
Lead Sponsor:
University of Medicine and Dentistry of New Jersey
Collaborator:
National Cancer Institute (NCI)
Treatments:
Capecitabine
Docetaxel
Gemcitabine